CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) (USD $) In Millions, unless otherwise specified	Jul. 01, 2012		Dec. 31, 2011
Assets
Cash and cash equivalents	$ 3,031		$ 3,182
Short-term investments	21,275		23,270
Accounts receivable, less allowance for doubtful accounts	12,882		13,058
Inventories	7,001		6,610
Taxes and other current assets	9,215		9,380
Assets of discontinued operations and other assets held for sale	5,361		5,317
Total current assets	58,765		60,817
Long-term investments	10,548		9,814
Property, plant and equipment, less accumulated depreciation	14,756		15,921
Goodwill	44,568		44,569
Identifiable intangible assets, less accumulated amortization	48,399	[1]	51,184	[1]
Taxes and other noncurrent assets	5,806		5,697
Total assets	182,842		188,002
Liabilities and Equity
Short-term borrowings, including current portion of long-term debt	7,703	[2]	4,016	[2]
Accounts payable	3,165		3,678
Dividends payable	1,826		1,796
Income taxes payable	2,098		1,009
Accrued compensation and related items	1,493		2,120
Other current liabilities	13,215		15,066
Liabilities of discontinued operations	1,298		1,224
Total current liabilities	30,798		28,909
Long-term debt	30,868	[3],[4]	34,926	[3],[4]
Pension benefit obligations	6,484		6,341
Postretirement benefit obligations	3,309		3,344
Noncurrent deferred tax liabilities	18,487		18,861
Other taxes payable	7,099		6,886
Other noncurrent liabilities	5,836		6,114
Total liabilities	102,881		105,381
Commitments and Contingencies
Preferred stock	42		45
Common stock	447		445
Additional paid-in capital	72,027		71,423
Employee benefit trusts	(2)		(3)
Treasury stock	(34,863)		(31,801)
Retained earnings	47,904		46,210
Accumulated other comprehensive loss	(6,008)		(4,129)
Total Pfizer Inc. shareholders' equity	79,547		82,190
Equity attributable to noncontrolling interests	414		431
Total equity	79,961		82,621
Total liabilities and equity	$ 182,842		$ 188,002

[1] The decrease is primarily related to amortization, as well as impairment charges (see Note 4. Other Deductions-Net), partially offset by the assets acquired as part of the acquisitions of Ferrosan and Alacer (see Note 2A. Acquisitions and Divestitures: Acquisitions).

[2] The differences between the estimated fair values and carrying values of these financial assets and liabilities not measured at fair value on a recurring basis were not significant as of July 1, 2012 or December 31, 2011. Held-to-maturity debt securities and our short-term and long-term debt fair value are based on Level 2 valuations using a market approach. Fair value measurements for private equity securities are based on Level 3 valuations using a market approach.

[3] Includes foreign currency debt with fair values of $885 million as of July 1, 2012 and $919 million as of December 31, 2011, which are used as hedging instruments.

[4] The fair value of our long-term debt is $35.5 billion as of July 1, 2012 and $40.1 billion as of December 31, 2011.